Discovery Collaborations with Forest Labs on Obesity targets

AURIGENE AND FOREST LABORATORIES TO COLLABORATE ON DEVELOPMENT OF NOVEL ORAL THERAPEUTICS FOR OBESITY AND METABOLIC DISORDERS BANGALORE, India and NEW YORK, February 2nd, 2007– Aurigene Discovery Technologies, Ltd (Aurigene),

Orion and Aurigene to Collaborate on First in Class Drugs for Cancer Treatment

ORION, FINLAND AND AURIGENE, INDIA, TO COLLABORATE ON DEVELOPMENT OF FIRST IN CLASS DRUGS FOR CANCER TREATMENT BANGALORE, India and ESPOO, Finland, April 25th 2007– Aurigene Discovery Technologies, Ltd (Aurigene),

Aurigene Achieves 2nd Milestone in Second Discovery Partnership With MerckSerono

Bangalore, India, June 24th, 2008 – Aurigene Discovery Technologies Ltd., a fully integrated, global biotech focused on small molecule and peptide drug discovery and development from target identification and validation

Aurigene in licensing agreement with Debiopharm

Bangalore, India and Lausanne, Switzerland, November 24, 2008 – Debiopharm Group (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies

Aurigene Announced Significant Milestone in a Collaboration Program

Aurigene has announced the achievement of a significant pre-clinical milestone in a Discovery collaboration with Novartis Pharma AG, Switzerland. Aurigene, which entered into a collaboration with Novartis in October, 2007,

Aurigene Announces Completion of Purchase of Discovery Research Facility in Hyderabad

Aurigene has completed the purchase of an additional site in Hyderabad with a fully integrated infrastructure and complement of high-quality and experienced scientific staff for Drug Discovery. This facility, along

Aurigene and Pcovery in pact to undertake anti-fungal drug discovery

Aurigene Discovery Technologies Ltd. today announced a drug discovery deal with Danish start-up Pcovery. Under the terms of this agreement, Aurigene and Pcovery will work collaboratively to progress early hits

Debiopharm Group™ and Aurigene nominate development candidate Debio 0617, a novel inhibitor of an undisclosed oncology pathway

Lausanne, Switzerland and Bangalore, India September 8, 2010 –Debiopharm Group (Debiopharm), a Swiss-based global biopharmaceutical group of companies with a focus on the development of innovative prescription drugs that target

Debiopharm and Aurigene sign agreement for the development and commercialisation of Debio 1142, a novel inhibitor of an undisclosed oncology pathway

Lausanne, Switzerland, and Bangalore, India, April 14, 2011 – Debiopharm Group™ (Debiopharm), a global biopharmaceutical development specialist that focuses on serious medical conditions and particularly oncology, and Aurigene Discovery Technologies